Controlled extracellular matrix degradation in breast cancer tumors improves therapy by trastuzumab

Keyphrases

• Trastuzumab 100%
• Extracellular Matrix Degradation 100%
• Relaxin 100%
• Breast Cancer Tumor 100%
• Tumor 50%
• Tumor Growth 50%
• Hematopoietic Stem Cells 50%
• Her2neu 50%
• Extracellular Matrix Protein 1 (ECM1) 50%
• Trastuzumab Therapy 50%
• Monoclonal Antibody 25%
• Mouse Model 25%
• Solid Tumors 25%
• Chemotherapy 25%
• Breast Cancer Patients 25%
• Malignant Cells 25%
• T Cells 25%
• Immunohistochemical Study 25%
• Syngeneic 25%
• Treatment Refractory 25%
• Treatment Strategy 25%
• Extracellular Matrix 25%
• Tumor Antigen 25%
• Anticancer Treatment 25%
• Cell-based 25%
• Colocalization 25%
• Cell-mediated 25%
• Tumor Expression 25%
• Peptide Hormone 25%
• Breast Cancer Xenograft 25%
• Retroviral Transduction 25%
• Antibody Therapy 25%
• Refractory Tumors 25%
• Tumor Extracellular Matrix 25%
• Tumor Section 25%
• Epithelial Tumors 25%
• Tumor-derived 25%
• BT474 25%
• Trastuzumab/Herceptin 25%
• Target Receptors 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Breast Cancer 100%
• Trastuzumab 100%
• Relaxin 80%
• Neoplasm 60%
• Tumor Growth 40%
• Scleroprotein 40%
• Solid Malignant Neoplasm 20%
• Malignant Neoplasm 20%
• Monoclonal Antibody 20%
• Mouse Model 20%
• Receptor 20%
• Tumor Antigen 20%
• Epithelium Tumor 20%
• Gene Delivery 20%
• Peptide Hormone 20%
• Chemotherapy Regimen 20%

Immunology and Microbiology

• Extracellular Matrix 100%
• Trastuzumab 100%
• Hematopoietic Cell 33%
• Matrix Protein 33%
• Monoclonal Antibody 16%
• T Cell 16%
• Xenograft 16%
• Mouse Model 16%
• Syngenic 16%
• Tumor Antigen 16%
• Viral Gene Delivery System 16%
• Masking 16%
• Peptide Hormone 16%